Cleared Traditional

K243274 - CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2) (FDA 510(k) Clearance)

Also includes:
Influenza A SubTyping Kit (VER 4) Influenza B Genotyping Kit (VER 1.1 and 2) and Influenza A/H5 Subtyping Kit (VER 4)
Jul 2025
Decision
268d
Days
Class 2
Risk

K243274 is an FDA 510(k) clearance for the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2). This device is classified as a Influenza A And Influenza B Multiplex Nucleic Acid Assay (Class II - Special Controls, product code OZE).

Submitted by Centers For Disease Control and Prevention (Atlanta, US). The FDA issued a Cleared decision on July 11, 2025, 268 days after receiving the submission on October 16, 2024.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3980. An Influenza A And Influenza B Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Influenza A And Influenza B Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Influenza A And B Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Influenza Viral Infections If Used In Conjunction With Other Clinical And Laboratory Findings..

Submission Details

510(k) Number K243274 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 16, 2024
Decision Date July 11, 2025
Days to Decision 268 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code OZE — Influenza A And Influenza B Multiplex Nucleic Acid Assay
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3980
Definition An Influenza A And Influenza B Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Influenza A And Influenza B Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Influenza A And B Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Influenza Viral Infections If Used In Conjunction With Other Clinical And Laboratory Findings.